OncoCyte (NYSEAMERICAN:OCX)‘s stock had its “buy” rating reiterated by Chardan Capital in a report released on Friday, TipRanks reports. They presently have a $7.75 price target on the biotechnology company’s stock. Chardan Capital’s target price suggests a potential upside of 366.87% from the company’s current price.
Separately, Zacks Investment Research downgraded OncoCyte from a “buy” rating to a “hold” rating in a research note on Wednesday, July 24th. One analyst has rated the stock with a hold rating and five have issued a buy rating to the stock. The stock currently has a consensus rating of “Buy” and a consensus target price of $6.05.
OCX stock traded up $0.05 during midday trading on Friday, reaching $1.66. The company had a trading volume of 307,489 shares, compared to its average volume of 554,229. OncoCyte has a fifty-two week low of $1.16 and a fifty-two week high of $6.92.
In other OncoCyte news, CEO Thomas Alex Vetter purchased 11,000 shares of the business’s stock in a transaction dated Wednesday, September 11th. The shares were bought at an average price of $9.58 per share, with a total value of $105,380.00. Also, major shareholder Broadwood Partners, L.P. purchased 2,000,000 shares of the business’s stock in a transaction dated Wednesday, September 11th. The shares were acquired at an average cost of $1.66 per share, for a total transaction of $3,320,000.00. In the last ninety days, insiders have bought 3,247,471 shares of company stock worth $5,553,481.
Several institutional investors and hedge funds have recently added to or reduced their stakes in OCX. Commonwealth Equity Services LLC raised its holdings in OncoCyte by 17.3% during the second quarter. Commonwealth Equity Services LLC now owns 35,206 shares of the biotechnology company’s stock worth $87,000 after purchasing an additional 5,200 shares in the last quarter. Acadian Asset Management LLC bought a new stake in OncoCyte during the second quarter worth approximately $30,000. Citadel Advisors LLC bought a new stake in OncoCyte during the second quarter worth approximately $38,000. Northern Trust Corp raised its holdings in OncoCyte by 32.4% during the second quarter. Northern Trust Corp now owns 73,973 shares of the biotechnology company’s stock worth $184,000 after purchasing an additional 18,100 shares in the last quarter. Finally, Weiss Asset Management LP bought a new stake in OncoCyte during the second quarter worth approximately $47,000.
OncoCyte Company Profile
OncoCyte Corporation focuses on the development and commercialization of novel and non-invasive blood and urine (liquid biopsy) diagnostic tests for the early detection of cancer. The company is developing diagnostic tests using genetic and protein markers expressed in various types of cancer. It develops diagnostic tests based on liquid biopsies using blood or urine samples for detecting lung, bladder, and breast cancer.
See Also: What is the definition of arbitrage?
Receive News & Ratings for OncoCyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OncoCyte and related companies with MarketBeat.com's FREE daily email newsletter.